DEVELOPMENT OF STEM CELL-BASED CANCER THERAPY STRATEGIES
Downloads
Cancer remains one of the leading causes of death worldwide, with various treatment options available depending on the type and stage of the disease. Traditional therapies, such as surgery, radiotherapy, chemotherapy, and immunotherapy, have shown varying degrees of success, but each has its limitations. Recently, stem cell therapies have emerged as a promising alternative, offering more targeted treatments with fewer side effects. Stem cells, including mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPSCs), and cancer stem cells (CSCs), have demonstrated potential in cancer therapy through mechanisms like tumor site targeting, paracrine signaling, and gene delivery. MSCs, in particular, are of interest due to their ability to migrate to tumor sites and release exosomes that can influence tumor growth, angiogenesis, and metastasis. Modified MSCs have been engineered to deliver anticancer agents or "suicide" genes, providing a more focused approach to tumor treatment. Moreover, MSCs have shown promise in addressing challenges like drug resistance and recurrence in cancer. However, their effectiveness depends on factors such as exosome composition and the tumor microenvironment. Despite the challenges, stem cell-based therapies, including MSC-derived exosomes, represent a novel strategy to enhance the specificity and efficacy of cancer treatments. This review explores current advances in stem cell-based cancer therapies, highlighting their potential, ongoing research, and the need for further studies to optimize these approaches for clinical application.
Aldoghachi, A. F., Chong, Z. X., Yeap, S. K., Cheong, S. K., Ho, W. Y. and Ong, A. H. K. (2023), “Stem Cells for Cancer Therapy: Translating the Uncertainties and Possibilities of Stem Cell Properties into Opportunities for Effective Cancer Therapy”, International Journal of Molecular Sciences, Vol. 24 No. 2, pp. 1012.
Aravindhan, S., Ejam, S. S., Lafta, M. H., Markov, A., Yumashev, A. V. and Ahmadi, M. (2021), “Mesenchymal stem cells and cancer therapy: insights into targeting the tumour vasculature”, Cancer Cell International, Vol. 21 No. 1, pp. 158.
Bhaumik, S. (2011), “Advances in imaging gene-directed enzyme prodrug therapy”, Current Pharmaceutical Biotechnology, Vol. 12 No. 4, pp. 497-507.
Chang, J. C. (2016), “Cancer stem cells Role in tumor growth, recurrence, metastasis, and treatment resistance”, Medicine, Vol. 95, pp. S20-S25.
Choi, Y., Lee, H. K. and Choi, K. (2023), “Engineered adult stem cells: a promising tool for anti-cancer therapy”, BMB Reports, Vol. 56 No. 2, pp. 71-7.
Chu, D., Nguyen, T. T., Tien, N. L. B., Tran, D., Jeong, J., Anh, P. G., Thanh, V. V., Truong, D. T. and Dinh, T. C. (2020), “Recent Progress of Stem Cell Therapy in Cancer Treatment: Molecular Mechanisms and Potential Applications”, Cells, Vol. 9 No. 3, pp. 563.
Copelan, E. A. (2006), “Hematopoietic stem-cell transplantation”, The New England Journal of Medicine, Vol. 354 No. 17, pp. 1813-26.
Danks, M. K. and Potter, P. M. (2004), “Enzyme-prodrug systems: carboxylesterase/CPT-11”, Methods in Molecular Medicine, Vol. 90, pp. 247-62.
Ghaedi, M., Soleimani, M., Taghvaie, N. M., Sheikhfatollahi, M., Azadmanesh, K., Lotfi, A. S. and Wu, J. (2011), “Mesenchymal stem cells as vehicles for targeted delivery of anti-angiogenic protein to solid tumors”, The Journal of Gene Medicine, Vol. 13 No. 3, pp. 171-80.
Gomes, J. P. A., Assoni, A. F., Pelatti, M., Coatti, G., Okamoto, O. K. and Zatz, M. (2017), “Deepening a Simple Question: Can MSCs Be Used to Treat Cancer?”, Anticancer Research, Vol. 37 No. 9, pp. 4747-58.
Guescini, M., Genedani, S., Stocchi, V. and Agnati, L. F. (2010), “Astrocytes and Glioblastoma cells release exosomes carrying mtDNA”, Journal of neural transmission, Vol. 117 No. 1, pp. 1-4.
Gutova, M., Flores, L., Adhikarla, V., Tsaturyan L., Tirughana, R., Aramburo, S., Metz, M., Gonzaga, J., Annala, A., Synold, T. W., Portnow, J., Rockne, R. C. and Aboody, K. S. (2019), “Quantitative Evaluation of Intraventricular Delivery of Therapeutic Neural Stem Cells to Orthotopic Glioma”, Frontiers in Oncology, Vol. 9.
Jain, R. K., di Tomaso, E., Duda, D. G., Loeffler, J. S., Sorensen, A. G. and Batchelor, T. T. (2007), “Angiogenesis in brain tumours”, Nature Reviews. Neuroscience, Vol. 8 No. 8, pp. 610-22.
Kanojia, D., Balyasnikova, I. V., Morshed, R. A., Frank, R. T., Yu, D., Zhang, L., Spencer, D. A., Kim, J. W., Han, Y., Yu, D., Ahmed, A. U., Aboody, K. S. and Lesniak, M. S. (2015), “Neural Stem Cells Secreting Anti-HER2 Antibody Improve Survival in a Preclinical Model of HER2 Overexpressing Breast Cancer Brain Metastases”, Stem Cells, Vol. 33 No. 10, pp. 2985-94.
Khiatah, B., Qi, M., Du, W., T-Chen, K., van Megen, K. M., Perez, R. G., Isenberg, J. S., Kandeel, F., Roep, B. O., Ku, H. T. and Al-Abdullah, I. H. (2019), “Intra-pancreatic tissue-derived mesenchymal stromal cells: a promising therapeutic potential with anti-inflammatory and pro-angiogenic profiles”, Stem Cell Research & Therapy, Vol. 10 No. 1, pp. 322.
Knoor, D. A., Ni, Z., Hermanson, D., Hexum, M. K., Bendzick, L., Cooper, L. J. N., Lee, D. A. and Kaufman, S. (2013), “Clinical-Scale Derivation of Natural Killer Cells From Human Pluripotent Stem Cells for Cancer Therapy”, Stem Cells Translational Medicine, Vol. 2 No. 4, pp. 274-83.
Ko, T., Lin, J., Hu, C., Hsu, Y., Wang, A. H. and Liaw, S. (2003), “Crystal structure of yeast cytosine deaminase. Insights into enzyme mechanism and evolution”, The Journal Biological Chemistry, Vol. 278 No. 21, pp. 19111-7.
Lin, W., Huang, L., Li, Y., Fang, B., Li, G., Chen L. and Xu, L. (2019), “Mesenchymal Stem Cells and Cancer: Clinical Challenges and Opportunities”, BioMed Research International, Vol. 2019.
Neviani, P. and Fabbri, M. (2015), “Exosomic microRNAs in the tumor microenvironment”, Frontiers in Medicine, Vol. 2 No. 47.
Raposo, G. and Stoorvogel, W. (2013), “Extracellular vesicles: Exosomes, microvesicles, and friends”, The Journal of Cell Biology, Vol. 200 No. 4, pp. 373-83.
Ratajczak, J., Miekus, K., Kucia, M., Zhang, J., Reca, R., Dvorak, P. and Ratajczak, M. Z. (2006), “Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery”, Leukemia, Vol. 20 No. 5, pp. 847-56.
Ruella, M. and Kenderian, S. S. (2017), “Next Generation Chimeric Antigen Receptor T Cell Therapy: Going off the Shelf”, BioDrugs, Vol. 31 No. 6, pp. 473-81.
Siegel, R. L., Miller, K. D. and Jemal, A. (2016), “Cancer Statistics, 2016”, CA: A Cancer Journal for Clinicians, Vol. 66 No. 1, pp. 7-30.
Takahashi, K. and Yamanaka, S. (2006), “Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors”, Cell, Vol. 126 No. 4, pp. 663-76.
Wang, C., Natsume, A., Lee, H. J., Motomura, K., Nishimira, Y., Ohno, M., Ito, M., Kinjo, S., Momota, H., Iwami, K., Ohka, F., Wakabayashi, T. and Kim, S. U. (2012), “Neural stem cell-based dual suicide gene delivery for metastatic brain tumors”, Cancer Gene Therapy, Vol. 19 No. 11, pp. 796-801.
Zheng, L., Zhang, D., Chen, X., Yang, L., Wei, Y. and Zhao, X. (2012), “Antitumor activities of human placenta-derived mesenchymal stem cells expressing endostatin on ovarian cancer”, PloS One, Vol. 7 No. 7.
Copyright (c) 2024 Sumadi, Rizki Zeillatul Warda
This work is licensed under a Creative Commons Attribution 4.0 International License.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without ristrictions.
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution (CC BY).
